WO1992014478A1 - Process for producing a medical composition with a bone marrow protective effect and an anti-neoplastic effect - Google Patents
Process for producing a medical composition with a bone marrow protective effect and an anti-neoplastic effect Download PDFInfo
- Publication number
- WO1992014478A1 WO1992014478A1 PCT/EP1992/000361 EP9200361W WO9214478A1 WO 1992014478 A1 WO1992014478 A1 WO 1992014478A1 EP 9200361 W EP9200361 W EP 9200361W WO 9214478 A1 WO9214478 A1 WO 9214478A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- coli
- metabolic products
- medicament
- ginkgo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to the manufacture of a medicament preparation for achieving a bone marrow-protective effect by stimulating leukocyte proliferation, a pharmaceutical preparation which contains such a medicament, and a medicament kit and a method for stimulating leukocyte proliferation and for producing an antineoplastic Effect.
- leukopenia occurs in patients who are treated with chemotherapy with cytostatics or with radiation, which can lead to a possibly severe anemia through thrombopenia. For this reason, cytostatics cannot be administered in unrestrictedly high doses in chemotherapy.
- the aim of the invention is therefore to overcome the aforementioned parts.
- Such a product is already marketed under the name Coiibi ⁇ genS as a medicament by Laves-Arzneistoff GmbH GmbH Ronnenberg / Hanover in Germany, both as an oral solution and as an injectable solution.
- an ampoule intended for injection contains 2 ml of a protein-free solution of the metabolic products of four trillion E. coli bacteria.
- Indications for this medicinal product are intestinal disorders of organic and functional genesis, especially with spastic symptoms, Crohn's disease, ulcerative collitis, urticaria, eczema, purpura, food allergy, bronchial asthma, spastic bronchitis, acne and migraines.
- Indications for the oral drinking solution are disorders of the motility and permeability of the intestinal mucosa, their damage, damage to the intestinal flora after the use of chemotherapy and antibiotic therapy, intestinal metabolic and resorption disorders, gastroenteritis salmonellosa, colidyspepsia, especially in small children and infants, endogenous enzyme, chronic loss of appetite and umbilical colic indicated.
- a filtrate essentially shows a polysaccharide component which consists mainly of glucose, galactose and xylose. Also included
- REPLACEMENT LEAF are peptide components which essentially contain asparagine, glutamic acid, alanine, glycerol, lysine and leucine. There is also a small proportion of fatty acids, in particular palmitic, stearic and oleic acid. Finally, small amounts of 3-hydroxymyristic acid and small amounts of bacterial endotoxin can also be found in this filtered solution from E. coli extract.
- the invention therefore relates to a method for producing a medicament for the above-mentioned new indications using a bacteria- and protein-free filtrate containing the metabolic products of E. coli cultures.
- a method for producing a medicament for the above-mentioned new indications using a bacteria- and protein-free filtrate containing the metabolic products of E. coli cultures is very particularly suitable for use in chemotherapy with cytostatics on cancer patients.
- the agent is also effective in radiation therapy.
- the patient is usually given at least one of the two pharmaceutical preparations in advance over a period of 2 hours to 5 minutes, expediently over 1 to 0.5 hours before administration of the cytostatic agent or radiation. All of the two drugs are preferably administered. Even if the pre-release is carried out 1 to 2 days before the radiation and / or chemotherapy, there are good effects. Even with a continuous oral. Administration, the surprising effect on which the invention is based is found.
- the protective effect on which the invention is based can be achieved for all known chemical cytostatics.
- the combination with the medicament produced according to the invention is subject to the usual conditions known to the doctor. selected for the respective tumor type.
- Preferred cytostatics for application to colon and gastric carcinoma are fluorouracil, and for breast cancer fluorouracil, cyclophosphate, epirubicin, methotrexate, to squamous cell carcinoma. Vepesid and Platinex.
- the medicament produced according to the invention has a particularly good effect on squamous cell carcinoma.
- the pharmaceutical manufactured according to the invention is therefore particularly suitable for the treatment of those tumors which have already undergone multiple cytotoxic chemotherapy and which otherwise show a very unfavorable response.
- the medicament produced in accordance with the invention is therefore particularly particularly suitable for the treatment of metastatic tumors.
- the invention therefore also relates to a pharmaceutical preparation which, in combination, precedes the metabolic products.
- E. coli-containing extract as a bacterial and protein-rich filtrate and an extract from Ginkgo biloba leaves.
- the production of such extracts is known and these can already be purchased from various manufacturers. For example, Dr. Willmar Schwabe, Düsseldorf, Germany marketed an extract standardized on ginkgo-flavone glycosides under the name TeboninR as a drug, drops and infusion ampoules.
- antineoplastic effect of the combined drugs cytostatics and the E. coli metabolic products can be increased even further if additional substances are administered which are contained in an extract from Ginkgo biloba leaves. Through the additional administration of such an extract, even those tumors and metastases show remission that have not previously responded to any medication or any other form of therapy. An increased effect can also be found in radiation therapy.
- the invention therefore also relates to a pharmaceutical preparation which, in combination, contains the metabolites from E. coli as a bacteria- and protein-free filtrate and an extract from Ginkgo biloba leaves.
- the pharmaceutical preparation can contain the metabolic products from E. coli and the extract from ginkgo biloba leaves both in mixed form and spatially separated for simultaneous, separate or staggered use.
- the extract from ginkgo leaves according to ginkgo-flavone glycosides is preferably contained in the pharmaceutical preparation according to the invention in a standardized manner.
- coli metabolic products and / or the extract from ginkgo leaves is preferably in an intravenously administrable form and expediently as an infusion and / or as injection ampoules.
- the effect according to the invention can also be achieved by continuous oral administration of ginkgo extract and E. coli filtrate.
- the pharmaceutical preparation according to the invention additionally contains a cytostatic in spatially separate form for simultaneous, separate or staggered use.
- the pharmaceutical preparation according to the invention is preferably used before the use of radiation and / or cytostatics applied as a default. It is preferably suitable for the treatment of tumor diseases, in particular for the treatment of breast cancer, prostate cancer, gastric cancer, esophageal cancer, squamous cell carcinoma, sarcoma, bile duct cancer, colon cancer or melanoma.
- Example 1 As described in Example 1, other patients who had gastric carcinoma, esophageal carcinoma and squamous cell carcinoma. and who previously did not respond to therapy, successfully with a combination of ginkgo extract, E. coli filtrate and cytostatic treated. In all cases a clear remission could be achieved by administration of the pharmaceutical combination according to the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEEP9200361T DE4290471D2 (en) | 1991-02-22 | 1992-02-20 | Process for the preparation of a pharmaceutical preparation for achieving a bone marrow-protective effect and an antineoplastic effect |
JP4504906A JPH06505016A (en) | 1991-02-22 | 1992-02-20 | Method for manufacturing pharmaceutical preparations for bone marrow protective and antitumor effects |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4105570A DE4105570A1 (en) | 1991-02-22 | 1991-02-22 | USE OF A BACTERIA- AND PROTEIN-FREE FILTRATE |
DEP4105570.5 | 1991-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992014478A1 true WO1992014478A1 (en) | 1992-09-03 |
Family
ID=6425657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/000361 WO1992014478A1 (en) | 1991-02-22 | 1992-02-20 | Process for producing a medical composition with a bone marrow protective effect and an anti-neoplastic effect |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0572470A1 (en) |
JP (1) | JPH06505016A (en) |
AU (1) | AU1246692A (en) |
CA (1) | CA2101645A1 (en) |
DE (2) | DE4105570A1 (en) |
HU (1) | HUT74576A (en) |
WO (1) | WO1992014478A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4308443A1 (en) * | 1993-03-17 | 1994-09-22 | Laves Hans Georg | Medicines used to treat retrovirus infections |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2378052C (en) * | 1999-08-12 | 2010-03-23 | Katy Drieu | Use of ginkgo extract |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0373986A1 (en) * | 1988-12-02 | 1990-06-20 | Abraxas Bio Labs S.A. | Anti-virus composition and its uses |
-
1991
- 1991-02-22 DE DE4105570A patent/DE4105570A1/en not_active Withdrawn
-
1992
- 1992-02-20 AU AU12466/92A patent/AU1246692A/en not_active Abandoned
- 1992-02-20 HU HU9302387A patent/HUT74576A/en unknown
- 1992-02-20 WO PCT/EP1992/000361 patent/WO1992014478A1/en not_active Application Discontinuation
- 1992-02-20 JP JP4504906A patent/JPH06505016A/en active Pending
- 1992-02-20 DE DEEP9200361T patent/DE4290471D2/en not_active Expired - Lifetime
- 1992-02-20 EP EP92904934A patent/EP0572470A1/en not_active Withdrawn
- 1992-02-20 CA CA002101645A patent/CA2101645A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0373986A1 (en) * | 1988-12-02 | 1990-06-20 | Abraxas Bio Labs S.A. | Anti-virus composition and its uses |
Non-Patent Citations (2)
Title |
---|
BUNDESVERBAND DER PHARMAZEUTISCHEN INDUSTRIE E.V, 'ROTE LISTE 1991' , EDITIO CANTOR , AULENDORF 59-383 COLIBIOGEN * |
BUNDESVERBAND DER PHARMAZEUTISCHEN INDUSTRIE E.V. 'ROTE LISTE 1991' , EDITIO CANTOR , AULENDORF 36-004 TEBONIN * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4308443A1 (en) * | 1993-03-17 | 1994-09-22 | Laves Hans Georg | Medicines used to treat retrovirus infections |
WO1994021269A1 (en) * | 1993-03-17 | 1994-09-29 | Laves Hans Georg | Drugs for the treatment of retrovirus infections |
Also Published As
Publication number | Publication date |
---|---|
DE4290471D2 (en) | 1994-04-28 |
DE4105570A1 (en) | 1992-08-27 |
JPH06505016A (en) | 1994-06-09 |
CA2101645A1 (en) | 1992-08-23 |
EP0572470A1 (en) | 1993-12-08 |
AU1246692A (en) | 1992-09-15 |
HU9302387D0 (en) | 1993-11-29 |
HUT74576A (en) | 1997-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0142641B1 (en) | Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system | |
EP0225496A2 (en) | Immunostimulating polysaccharides from cell cultures of Echinacea purpurea (Linné) Moench and Echinacea angustifolia (De Vandolle), process for their preparation and pharmaceutical compositions containing them | |
EP0263417A1 (en) | Use of hyaluronidase | |
DE3115080A1 (en) | MEDICINAL PRODUCTS FOR ORAL ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF | |
EP0871437B1 (en) | Use of boswellic acid for treating brain tumours | |
DE60204067T2 (en) | Use of xanthenone-4-acetic acid for the manufacture of a medicament for the treatment of hyperproliferative disorders | |
WO1992014478A1 (en) | Process for producing a medical composition with a bone marrow protective effect and an anti-neoplastic effect | |
EP0359951B1 (en) | Use of a ginkgo extract against metastases | |
DE60030567T2 (en) | COMPOSITION COMPRISING MUSCLES DERIVED FROM MUSCLES | |
US5229373A (en) | Use of exogenous gangliosides as a protective factor against toxicity by antitumor drug vincristine | |
DE2715384C3 (en) | Medicines for diarrhea | |
DE4429735C2 (en) | Plant redox catalyst, agent for the treatment of immunobiological cell load deficiencies and process for its preparation | |
DE10326821A1 (en) | Pharmaceutical combination preparations for cancer therapy | |
DE19738484A1 (en) | Use of N-propanoyl-mannosamine as a medicament | |
JPS5821655A (en) | Novel compound having remedial effect, and its preparation | |
DE69919040T2 (en) | USE OF A SYNERGISTIC COMPOSITION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF LIVER DISEASES | |
EP0210295B1 (en) | Medicine for the treatment of chronical inflammatory enterocolitis | |
DE3334751C2 (en) | ||
DE2265235A1 (en) | REMEDIES | |
Leupold et al. | Nichtketotische Hyperglycinämie | |
DE3410848A1 (en) | Pharmaceutical composition for the treatment of tumours in the metastasis phase | |
EP0951291A1 (en) | Cancer treatment drug | |
EP1309335B1 (en) | Use of extracts from ginkgo biloba leaves for inducing dreams | |
DE3915929A1 (en) | Polysaccharide from Nerium oleander - having immune-stimulating effect and stimulating tumour necrosis factor synthesis | |
DE3825186A1 (en) | Lectin-containing compositions which can be administered orally for treating metastases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992904934 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2101645 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1993 107810 Country of ref document: US Date of ref document: 19931208 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1992904934 Country of ref document: EP |
|
REF | Corresponds to |
Ref document number: 4290471 Country of ref document: DE Date of ref document: 19940428 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4290471 Country of ref document: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992904934 Country of ref document: EP |